B cells critical for outcome in high grade serous ovarian carcinoma
- PMID: 39175107
- DOI: 10.1002/ijc.35149
B cells critical for outcome in high grade serous ovarian carcinoma
Abstract
Recent work has shown evidence for the prognostic significance of tumor infiltrating B cells (B-TIL) in high grade serous ovarian carcinoma (HGSOC), the predominant histological subtype of ovarian cancer. However, it remains unknown how the favorable prognosis associated with B-TIL relates to the current standard treatments of primary debulking surgery (PDS) followed by chemotherapy or (neo-)adjuvant chemotherapy (NACT) combined with interval debulking surgery. To address this, we analyzed the prognostic impact of B-TIL in relationship to primary treatment and tumor infiltrating T cell status in a highly homogenous cohort of HGSOC patients. This analysis involved a combined approach utilizing histological data and high-dimensional flow cytometry analysis. Our findings indicate that while HGSOC tumors pre-treated with NACT are infiltrated with tumor-reactive CD8+ and CD4+ TIL subsets, only B-TIL and IgA plasma blasts confer prognostic benefit in terms of overall survival. Importantly, the prognostic value of B-TIL and IgA plasma blasts was not restricted to patients treated with NACT, but was also evident in patients treated with PDS. Together, our data point to a critical prognostic role for B-TIL in HGSOC patients independent of T cell status, suggesting that alternative treatment approaches focused on the activation of B cells should be explored for HGSOC.
Keywords: B cells; high grade serous ovarian cancer; tumor infiltrating lymphocytes.
© 2024 The Author(s). International Journal of Cancer published by John Wiley & Sons Ltd on behalf of UICC.
References
REFERENCES
-
- Colombo N, Sessa C, Du Bois A, et al. ESMO‐ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease. Ann Oncol. 2019;30(5):672‐705. doi:10.1093/annonc/mdz062
-
- Timmermans M, Sonke GS, Van de Vijver KK, van der Aa MA, Kruitwagen RFPM. No improvement in long‐term survival for epithelial ovarian cancer patients: a population‐based study between 1989 and 2014 in The Netherlands. Eur J Cancer. 2018;88:31‐37. doi:10.1016/j.ejca.2017.10.030
-
- Disilvestro P, Banerjee S, Colombo N, et al. Overall survival with maintenance Olaparib at a 7‐year follow‐up in patients with newly diagnosed advanced ovarian cancer and a BRCA mutation: the SOLO1/GOG 3004 trial. J Clin Oncol. 2023;41(3):609‐617. doi:10.1200/JCO.22.01549
-
- Cancer Genome Atlas Research Network T. Integrated genomic analyses of ovarian carcinoma. 2012. doi:10.1038/nature10166
-
- Paijens ST, Vledder A, Loiero D, et al. Prognostic image‐based quantification of CD8CD103 T cell subsets in high‐grade serous ovarian cancer patients. Onco Targets Ther. 2021;10(1). doi:10.1080/2162402X.2021.1935104
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Research Materials